This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Study Indicates DTaP's Efficacy Wanes After Final Dose
By News Staff
"Increasing time since the fifth dose of DTaP was associated with an increasing percentage of positive PCR tests," the authors wrote. "The time since the fifth dose of DTaP was significantly longer for PCR-positive children than for PCR-negative controls, (while) case children received their fifth dose of DTaP significantly earlier than controls ... indicating that each year after the fifth dose of DTaP was associated with a 42 percent increased (risk) of acquiring pertussis."
According to the study, DTaP's limited protection duration raises the question of whether the Tdap booster should be generally approved for children as young as eight. But before that can happen, several issues must be clarified, including Tdap's overall effectiveness and duration of protection.
"The findings suggest that whooping cough control measures may need to be reconsidered," lead author Nicola Klein, M.D., Ph.D. said in a news release. "Prevention of future outbreaks may be best achieved by developing new pertussis-containing vaccines or reformulating current vaccines to provide long-lasting immunity. That said, the DTaP vaccine is effective and remains an important tool for protection against whooping cough for children and the communities in which they live, and following current CDC recommendations remains important."